Treatment of tumor metastases and cancer

• US 20020098164A1
• Filed: 10/23/2001
• Published: 07/25/2002
• Est. Priority Date: 10/27/2000
• Status: Abandoned Application

• Current Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Original Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Inventors: Redmond, H. Paul, Pfirrmann, Rolf W.
• Application Number:
  US09/983,279
• Publication Number:
  US 20020098164A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/541 Non-condensed thiazines containing further heterocyclic rings
• CPC Class Codes: A61K 31/549 having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.

Claims

1. A method of inhibiting tumor metastasis in a cancer patient comprising administering to said patient a combination therapy comprising effective amounts of IL-2 and a methylol transfer agent.

2. The method of claim 1 wherein said tumor is a lymphoma, carcinoma or sarcoma.

3. The method of claim 1 wherein said tumor is a glioma, a neuroblastoma, an astrocytoma, carcinomatous meningitis, breast cancer, ovarian cancer, colon cancer, prostate cancer, pancreatic cancer, CNS cancer, liver cancer, lung cancer, gastric cancer, esophageal cancer, urinary bladder cancer, leukemia, melanoma, and renal cell cancer.

4. The method of claim 1 wherein said methylol transfer agent is taurolidine, taurultam, a biologically active derivative thereof, or a mixture thereof.

5. The method of claim 1 wherein said methylol transfer agent is taurolidine, taurultam or a mixture thereof.

6. The method of claim 5 wherein said tumor metastasis is metastatic malignant melanoma or metastatic renal cell carcinoma.

7. A method of treating cancer selected from the group consisting of renal cancer and malignant melanoma, in a patient having said cancer, comprising administering to said patient a combination therapy comprising effective amounts of interleukin-2 and a methylol transfer agent.

8. The method of claim 7 wherein said methylol transfer agent is taurolidine, taurultam, a biologically active derivative thereof, or a mixture thereof.

9. The method of claim 7 wherein said methylol transfer agent is taurolidine, taurultam or a mixture thereof.

10. In combination:

Interleukin-2 (IL-2) and a methylol transfer agent, in effective amounts for simultaneous, separate or sequential use for inhibiting tumor metastasis in a cancer patient.

11. The combination of claim 10 wherein said IL-2 and said methylol transfer agent are each present as a pharmaceutical dosage unit.

12. The combination of claim 11 wherein said methylol transfer agent is taurolidine, taurultam, a biologically active derivative thereof, or a mixture thereof.

13. The combination of claim 11 wherein said methylol transfer agent is taurolidine, taurultam or a mixture thereof.

14. A pharmaceutical combination comprising each of the pharmaceutical dosage units of claim 13, for use in inhibiting tumor metastasis in a cancer patient.

15. A pharmaceutical composition for use in inhibiting tumor metastasis in a cancer patient, comprising the combination of claim 14.